2016
DOI: 10.1002/ange.201601123
|View full text |Cite
|
Sign up to set email alerts
|

Metabolisches Glykoengineering mit N‐Acyl‐Seiten‐ ketten‐modifizierten Mannosaminen

Abstract: Beim metabolischen Glykoengineering (MGE) werden Zellen und Tiere mit nichtnatürlichen Derivaten von Monosacchariden behandelt. Diese werden nach ihrer Aufnahme ins Zytosol metabolisiert und anschließend auf neusynthetisierten Glykokonjugaten exprimiert. MGE wurde zuerst für sialylierte Glykane realisiert, mit N‐Acyl‐modifizierten Mannosaminen als Vorstufen für nichtnatürliche Sialinsäuren. Voraussetzung ist die Promiskuität der Enzyme des Roseman‐Warren‐Biosyntheseweges. Diese tolerieren spezifische Modifikat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 29 publications
(2 citation statements)
references
References 439 publications
(482 reference statements)
0
2
0
Order By: Relevance
“…Similar low labeling efficiencyo fN-acetylglucosamine (GlcNAc) derivatives was also observed by others.I t has been speculated that this effect is the result of restriction of GlcNAc in the sialic acid pathway and the ability of GlcNAc analogues to produce multiple metabolic products. [21][22][23] Fluorescence microscopy was furthermore used to image the labeled cells.For this,A549 cells were first incubated with 4a at 0.29 mm for 3days and then treated with P 2h -BSA-FITC for 1, 5, 10, 15, or 30 min. Thegreen fluorescence that resulted from P 2h -BSA-FITC was clearly seen on the cells ( Figure 5).…”
Section: Angewandte Chemiementioning
confidence: 99%
“…Similar low labeling efficiencyo fN-acetylglucosamine (GlcNAc) derivatives was also observed by others.I t has been speculated that this effect is the result of restriction of GlcNAc in the sialic acid pathway and the ability of GlcNAc analogues to produce multiple metabolic products. [21][22][23] Fluorescence microscopy was furthermore used to image the labeled cells.For this,A549 cells were first incubated with 4a at 0.29 mm for 3days and then treated with P 2h -BSA-FITC for 1, 5, 10, 15, or 30 min. Thegreen fluorescence that resulted from P 2h -BSA-FITC was clearly seen on the cells ( Figure 5).…”
Section: Angewandte Chemiementioning
confidence: 99%
“…Then, the second bioorthogonal component (usually dibenzocyclooctyne DBCO or azadibenzocyclooctyne ADIBO) reacts with the azide reporter through click bioorthogonal chemistry. The DBCO/ADIBO component can be attached to a fluorescent dye, prodrug or targeting peptide for labelling and imaging, targeted drug release or enhanced targeting profile, respectively [25,137–139] …”
Section: Targeting Mechanismsmentioning
confidence: 99%